Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Semaglutide Pen Injector [Ozempic]
Semaglutide Pen Injector · 3 trials · 6 indications
mean severity grade (0-II)
Measured as VAT/Subcutaneous Adipose Tissue + VAT changes over 1 year.
Hepatic insulin resistance, measured by serum concentration of beta-hydroxybutyrate (surrogate marker of acetyl-CoA, which regulates gluconeogenesis), changes over 1 year.
Change in triglycerides after a high-fat mixed meal tolerance test, expressed as the total Area Under the Curve (AUCTG) over 6 hours from baseline to 1 year.
Weight measured in kilograms
| Arm | Type | Description |
|---|---|---|
| Semaglutide | ACTIVE_COMPARATOR | Semaglutide active drug 0.25-0.5mg, once-weekly, injection |
| Placebo | PLACEBO_COMPARATOR | Semaglutide placebo, once-weekly, injection |
| Name | Type | Description |
|---|---|---|
| Semaglutide Pen Injector [Ozempic] | DRUG | Semaglutide active drug |
| Placebo | DRUG | semaglutide placebo |
| Semaglutide Pen Injector | DRUG | Escalated to 2.4mg or max tolerated dose |
Inclusion Criteria: * Referral for auto-HSCT for relapsed diffuse large B-cell lymphoma or follicular lymphoma * Age ≥ 18 years * BMI ≥ 18.5 * ECOG performance status\* ≤ 2 * Literate in Danish and/or English Exclusion Criteria: * Diabetes * Inflammatory bowel disease * Previous or current gastro...
Semaglutide Pen Injector is being studied for use in NAFLD, type 1 diabetes, and intestinal mucositis. It is an investigational small molecule in Phase 2 clinical development for these metabolic and inflammatory conditions.
Semaglutide Pen Injector is a peptide-based drug that targets the GLP-1 pathway. It is being evaluated for its effects on weight gain after liver transplant, obesity in type 1 diabetes, and inflammation related to chemotherapy.
Semaglutide Pen Injector is developed by Novo Nordisk A/S, a biopharmaceutical company. The company's stock is traded under the ticker symbol NVO on major exchanges.
Semaglutide Pen Injector is currently in Phase 2 clinical trials. It has received FDA accelerated approval designation, indicating it is being studied for serious conditions with unmet medical needs.
Semaglutide Pen Injector is being studied in three Phase 2 trials: NCT05424003 for NAFLD after liver transplant, NCT06411210 for obesity in type 1 diabetes, and NCT06449625 for intestinal mucositis. All are randomized, double-blinded, and placebo-controlled.
Yes, Semaglutide Pen Injector is also known as Ozempic. The drug is being investigated under this brand name in clinical trials for various metabolic conditions.